One dose (1 capsule) provides 300 mg of EPA and DHA combined, which is at the lower to mid end of the 250–1000 mg daily range that clinical research links to cardiovascular and anti-inflammatory benefits (ISSN Position Stand, 2025). This means that with 1 capsule you will reach a basic level of intake. If you have a specific goal (e.g., managing triglycerides) or want to reach the upper part of this range, consult your doctor or pharmacist about a higher dose, as the manufacturer recommends not exceeding the daily amount without such consultation.

Battery Omega 3 contains alpha-tocopherol (a form of vitamin E) as an antioxidant, which protects the unstable omega-3 fatty acids from oxidation or rancidity, but the manufacturer does not state the exact amount in milligrams on the label. This is a minor transparency shortcoming compared to products in this category that explicitly state the vitamin E content (e.g., 2 or 15 mg per dose). The mere presence of the antioxidant is still positive for the product's oxidative stability, but without a figure it's not possible to assess whether the amount is optimal.

The product is manufactured in a facility that also processes milk, eggs, gluten and soy, so it may contain traces thereof, which is clearly stated on the label. If you have a severe allergy to any of these ingredients, be careful and consult an allergist before use if needed. The product's main ingredient is fish oil, so the "fish" allergen is the key warning that applies to all users with a fish or seafood allergy.

For Battery Omega 3, there is no publicly available independent lab testing report in the available data, so it is currently not possible to externally confirm the declared EPA/DHA content or oxidative stability (TOTOX) – the quality assessment is therefore based solely on the manufacturer's label claims. If independent, batch-specific testing is an important criterion for you, the only product in this category currently with a publicly available report is GymBeam Omega 3, which has a published report from the GBA Group laboratory dated February 2026.